Evidence overview
Spermidine
Spermidine is a polyamine compound that has attracted attention as a potential autophagy-inducing anti-aging supplement. The human clinical evidence base is very small - dominated by short trials and observational dietary research - and no consensus documents or umbrella reviews specific to spermidine supplementation have been published. The supplement is in an early-research stage relative to the consumer attention it receives.
Most studied for
Coverage pending
PubMed coverage
Coverage pending
Safety profile
In your full report
Mechanism class
Polyamine compound found naturally in many foods (especially wheat germ, soy products, aged cheese,...
Study coverage
Study coverage by goal
PubMed counts for Spermidine grouped by the goal each study targets.
Evidence overview is temporarily unavailable for Spermidine.
Evidence
What the evidence covers
The terrain of the published literature, not its conclusions.
Spermidine is a polyamine compound found naturally in many foods - wheat germ (the most-common supplemental source), soy products, aged cheese, mushrooms, and others - and synthesized endogenously by the body. The supplement is studied for autophagy induction (the conceptual basis for anti-aging marketing), cognitive function in older adults (a small but growing research stream), cardiovascular and inflammatory markers, and broader longevity-adjacent outcomes. The clinical literature in humans is small and recent; most of what is known about spermidine comes from preclinical models, observational dietary research, and a handful of short randomized trials.
The outcome dimensions covered most heavily in the human literature are cognitive function in older adults with mild cognitive symptoms (the largest clinical research focus to date), inflammatory and cardiovascular markers, and broader autophagy-related biomarkers. The supplement-specific clinical evidence base is small enough that no Cochrane review, umbrella synthesis, or expert-society position document has been published. Observational research from dietary cohorts has examined associations between spermidine intake and various aging-related markers, though observational and supplementation evidence address different questions.
Demographically, the clinical-trial literature concentrates on older adults with mild cognitive symptoms or cardiovascular risk markers. Source variation matters: wheat germ extract is the dominant supplemental form, and spermidine content varies substantially between products. The gap between dietary intake (where observational evidence is suggestive) and supplemental intake (where clinical evidence is small) is a recurring methodological issue. The field is in an early stage relative to consumer attention, and many marketed claims rely substantially on mechanistic and preclinical reasoning rather than human clinical evidence.
Safety
Safety summary
Common adverse events, drug interactions, and special populations.
Spermidine is generally well-tolerated in the small human clinical trials conducted to date, at doses typically in the range of 1-6 mg/day delivered via wheat germ extract. The most-commonly reported adverse effects are mild gastrointestinal discomfort. No tolerable upper limit has been established. Drug interactions are not well-characterized in clinical research. Wheat germ extract sources are not appropriate for people with celiac disease, wheat allergy, or gluten sensitivity. The limited duration of available trials means long-term safety data are not available, which is a meaningful gap given the supplement's primary marketed use is long-term anti-aging.
This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.
Limitations
What this page doesn't answer
Where the public summary stops and the personalized report begins.
This page summarizes the spermidine literature at a general level. The most-important limitation is the emerging nature of the human clinical evidence: no Cochrane review, expert-society position document, or umbrella synthesis exists specifically for spermidine supplementation, and many marketed claims rest substantially on preclinical evidence and observational dietary research rather than supplementation-specific clinical trials. It does not address which product source is right for your situation, what dose has clinical support (the small-trial doses cluster around 1-6 mg/day), how long to take it, whether your dietary spermidine intake already provides comparable amounts, or how spermidine fits with your specific health context. The field is sufficiently early-stage that the personalized report can offer context rather than firm recommendations for many spermidine-related questions.
Personalized to you
Get a personalized Spermidine report
Your free first report adds the things this page doesn't: per-goal evidence breakdown, demographic-specific findings, full citation list, and a safety section tailored to your profile.
Free first report. No credit card. Cancel anytime.
Get notified when new evidence appears
We'll email you when the literature on Spermidine materially updates. No account required.